Fulfilling the promise of precision medicine through quality and innovation

by individualizing cancer treatments and pioneering a better molecular understanding of cancer

Caris Life Sciences believes personalized and precise information can change the face of cancer care

Our Platforms

To fulfill the promise of precision medicine and to facilitate a deeper understanding of the biology of cancer and other complex diseases, Caris Life Sciences® has developed a patented and proprietary biotargeting system. ADAPT Biotargeting System measures millions of molecular interactions within complex biological systems for drug target identification, therapeutic discovery and development, companion diagnostics, blood-based cancer screening, and biomarker identification.

Caris Life Sciences also pioneered the first molecular testing offering to help physicians make more informed treatment decisions. As the industry leader, our Comprehensive Genomic Profiling Plus (CGP+) approach assesses DNA, RNA and Proteins to reveal the molecular drivers of cancer that serves as a blueprint to enable the delivery of personalized medicine.

Identifying novel molecular targets for drug development and diagnostics

Learn More

Molecular testing to guide optimum treatment selection by physicians

Learn More
service image

Caris to Present New Data at ASCO 2017

Be sure to check out the 11 accepted clinical studies, including an oral abstract presentation and two poster discussions, at this year's ASCO Annual Meeting. The studies were conducted in collaboration with industry-leading academic and clinical institutions using Caris Molecular Intelligence, the company’s CGP+ molecular testing service.

service image

The Power of Immunotherapy

Immune checkpoint inhibitors are rapidly ushering in a new era of precision medicine. Comprehensive genomic and proteomic profiling with CMI can help oncologists identify patients more likely to respond to these novel drugs. Learn more about PD-L1, MSI and Total Mutational Load testing.

service image

Total Mutational Load

Total Mutational Load for Immunotherapy Response is an emerging, quantitative indicator for predicting response to novel immune checkpoint inhibitors across a wide spectrum of tumor types.

Since 2008 - A leader in diagnostic, prognostic and theranostic medicine
More than 117,000 clinical cases and counting

Physicians

When the next step in treatment is uncertain, Caris Life Sciences illuminates a clearer path to personalized treatment selection with our industry leading, patented and proprietary offering, Caris Molecular Intelligence. Also, learn how we are pioneering a new era in drug development and advanced diagnostics with our proprietary ADAPT Biotargeting System.

Visit Platforms Page

It’s time to treat cancer smarter

Patients

Although cancer treatments have significantly advanced over the years, current cancer care options are failing too many patients. It’s time to treat cancer smarter. An analysis of your cancer with Caris Molecular Intelligence may identify biomarkers that could lead towards a better understanding of what is causing your cancer to grow and inform personalized treatments to specifically target your cancer.

Visit Patients Page

Latest News and Social Media Posts

As a leader in precision healthcare and informatics, Caris Life Sciences is continually exploring new technologies and partnering with other trailblazers in the field. We’re always excited to share our most recent accomplishments and discoveries.

Visit News PortalSocial Media Posts